MapLight Therapeutics, Inc. MPLT Deferred Financing Costs Included In Accounts Payable And Accrued Expenses
Deferred Financing Costs Included In Accounts Payable And Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept mplt:DeferredFinancingCostsIncludedInAccountsPayableAndAccruedExpenses.
The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about MapLight Therapeutics, Inc. 's deferred financing costs included in accounts payable and accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MapLight Therapeutics, Inc. 's deferred financing costs included in accounts payable and accrued expenses?
- MapLight Therapeutics, Inc. (MPLT) reported deferred financing costs included in accounts payable and accrued expenses of $202K in Q1 2025.
- What does deferred financing costs included in accounts payable and accrued expenses mean?
- This metric represents the portion of financing-related costs that have been incurred but not yet paid in cash, remaining recorded as liabilities on the balance sheet. It provides insight into non-cash financing activities that impact working capital and future cash outflows. Monitoring this figure helps investors understand the extent to which capital-raising efforts are being accrued rather than immediately settled.